Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model

Pharmaceutical Research

Volumn 26, Issue 1, 2009, Pages 218-223

  Mittal, G ^a   Chandraiah, G ^b   Ramarao, P ^b   Ravi Kumar, M N V ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Bioavailability; Estrogen therapy; Lipid profile; Nanoparticles; Oral drug delivery

Indexed keywords

ESTRADIOL; NANOPARTICLE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; ESTROGEN DEFICIENCY; FEMALE; HYPERLIPIDEMIA; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT;

ANIMALS; CHOLESTEROL; DIET; DIETARY FATS; ESTRADIOL; FEMALE; HYPERLIPIDEMIAS; LACTIC ACID; NANOPARTICLES; OVARIECTOMY; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIGLYCERIDES;

EID: 57749182425     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9725-x     Document Type: Article

References (39)

1. J. C. Stevenson 2000 Cardiovascular effects of oestrogens J. Steroid Biochem. Mol. Biol 74 387 393
2. A. Pines 2002 Hormone therapy and the cardiovascular system Maturitas 43 Suppl. 1 S3 S10
3. G. I. Gorodeski 2002 Update on cardiovascular disease in postmenopausal women Best Pract. Res. Clin. Obstet. Gynaecol 16 329 355
4. B. J. Shen J. F. Todaro R. Niaura J. M. McCaffery J. Zhang A. Spiro III K. D. Ward 2003 Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome x Am. J. Epidemiol 157 701 711
5. M. Bottner W. Wuttke 2006 Chronic treatment with physiological doses of estradiol affects the GH-IGF-1 axis and fat metabolism in young and middle-aged ovariectomized rats Biogerontology 7 91 100
6. M. J. Stampfer G. A. Colditz 1991 Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence Prev. Med 20 47 63
7. F. Grodstein M. Stampfer 1995 The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women Prog. Cardiovasc. Dis 38 199 210
8. F. Grodstein M. J. Stampfer J. E. Manson G. A. Colditz W. C. Willett B. Rosner F. E. Speizer C. H. Hennekens 1996 Postmenopausal estrogen and progestin use and the risk of cardiovascular disease N. Engl. J. Med 335 453 461
9. T. Tolbert S. Oparil 2001 Cardiovascular effects of estrogen Am. J. Hypertens 14 186S 193S
10. J. C. Stevenson 1998 Various actions of oestrogens on the vascular system Maturitas 30 5 9
11. M. Abbey A. Owen M. Suzakawa P. Roach P. J. Nestel 1999 Effect of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity Maturitas 33 259 269
12. C. Livingstone M. Collison 2002 Sex steroids and insulin resistance Clin. Sci 102 151 166
13. M. L. Liu X. Xu W. Q. Rang Y. J. Li H. P. Song 2004 Influence of ovariectomy and 17β-estradiol treatment on insulin sensitivity, lipid metabolism and post-ischemic cardiac function Int. J. Cardiol 97 485 493
14. H. Esterbauter J. Gebicki H. Puhl G. Jurgens 1992 The role of lipid peroxidation and antioxidants in oxidative modification of LDL Free Radic. Biol. Med 13 341 390
15. J. A. Berliner J. W. Heinecke 1996 The role of oxidized lipoproteins in atherogenesis Free Radic. Biol. Med 20 707 727
16. V. A. Rifici A. K. Khachadurian 1992 The inhibition of low-density lipoprotein oxidation by 17-β estradiol Metabolism 41 1110 1114
17. M. Badeau H. Adlercreutz P. Kaihovaara M. J. Tikkanen 2005 Estrogen A-ring structure and antioxidative effect on lipoproteins J. Steroid Biochem. Mol. Biol 96 271 278
18. D. Crook 2001 Do we need clinical trials to test the ability of transdermal HRT to prevent coronary heart disease? Curr. Control Trials Cardiovasc. Med 2 211 214
19. R. A. Lobo 1995 Benefits and risks of estrogen replacement therapy Am. J. Obstet. Gynecol 173 982 989
20. J. D. Yager J. G. Liehr 1996 Molecular mechanism of estrogen carcinogenesis Annu. Rev. Pharmacol. Toxicol 36 203 232
21. J. W. Yoo C. H. Lee 2006 Drug delivery systems for hormone therapy J. Control. Release 112 1 14
22. A. T. Florence 1997 The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual Pharm. Res 14 259 266
23. D. A. Norris N. Puri P. J. Sinko 1998 The effect of physical barriers and properties on the oral absorption of particulates Adv. Drug Deliv. Rev 34 135 154
24. I. Bala S. Hariharan M. N. V. R. Kumar 2004 PLGA nanoparticles in drug delivery: The state of the art Crit. Rev. Ther. Drug Carr. Syst 21 387 422
25. A. T. Florence 2005 Nanoparticle uptake by the oral route: Fulfilling its potential? Drug Discov. Today Technol 2 75 81
26. V. Bhardwaj S. Hariharan I. Bala A. Lamprecht N. Kumar R. Panchagnula M. N. V. R. Kumar 2005 Pharmaceutical aspects of polymeric nanoparticles for oral delivery J. Biomed. Nanotechnol 1 235 258
27. S. Hariharan V. Bhardwaj I. Bala J. Sitterberg U. Bakowasky M. N. V. R. Kumar 2006 Design of estradiol loaded PLGA nanoparticulate formulations: A potential oral delivery system for hormone therapy Pharm. Res 23 184 195
28. G. Mittal D. K. Sahana V. Bhardwaj M. N. V. R. Kumar 2007 Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo J. Control Release 119 77 85
29. D. K. Sahana G. Mittal V. Bhardwaj M. N. V. R. Kumar 2008 PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug J. Pharm. Sci 97 1530 1542
30. K. Srinivasan B. Viswanad L. Asrat C. L. Kaul P. Ramarao 2005 Combination of high-fat diet-fed and low-dose streptozotocin treated rat: A model for type 2 diabetes and pharmacological screening Pharmacol. Res 52 313 320
31. P. Parini B. Angelin A. Stavreus-Evers B. Freyschuss H. Eriksson M. Rudling 2000 Biphasic effects of the natural estrogen 17β-estradiol on hepatic cholesterol metabolism in intact female rats Arterioscler. Thromb. Vasc. Biol 20 1817 1823
32. D. D. Ankola V. Boomi V. Bhardwaj P. Ramarao M. N. V. R. Kumar 2007 Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: Can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Eur. J. Pharm. Biopharm 67 361 369
33. A. K. Meena D. V. Ratnam G. Chandraiah D. D. Ankola P. Ramarao M. N. V. R. Kumar 2008 Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to lipicure® in treating hyperlipidemia Lipids 43 231 241
34. D. V. Ratnam G. Chandraiah K. Sonaje V. Boomi V. Bhardwaj P. Ramarao M. N. V. R. Kumar 2008 A potential therapeutic strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q10: Preparation and evaluation in streptozotocin induced diabetic rats J. Biomed. Nanotechnol 4 33 43
35. H. Ohkawa N. Ohishi K. Yagi 1979 Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem 95 351 358
36. M. Shinoda M. G. Latour J. M. Lavoie 2002 Effects of physical training on body composition and organ weights in ovariectomized and hyperestrogenic rats Int. J. Obes 26 335 343
37. S. G. Lundeen J. M. Carver M. L. Mckean R. C. Winneker 1997 Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels Endocrinology 138 1552 1558
38. C. Lemieux Y. Ge'linas J. Lalonde F. Labrie D. Richard Y. Deshaies 2006 Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia Metab. Clin. Exp 55 605 613
39. I. Dalle-Donne R. Rossi R. Colombo D. Giustarini A. Milzani 2006 Biomarkers of oxidative damage in human disease Clin. Chem 52 601 623